IRCT20230415057912N1 IRCT 2023-12-07 Esfahan University of Medical Sciences efficacy and safety of oral pioglitazone in treatment of lichen planopilaris efficacy and safety of adding oral pioglitazone to standard treatment in lichen planopilaris 2023-05-01 anticipated 30 Complete https://irct.ir/trial/69880 interventional Randomization: Randomized, Blinding: Triple blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: By random allocation software, they are divided into two treatment groups with methotrexate and methotrexate and pioglitazone, and patients are selected by a simple random table, Blinding description: The patient and the main executive of the plan, those who check the outcome, know that there are two treatment groups, but the assistant of the main executive knows who is in which group. 3 Lichen planopilaris. Intervention 1: Intervention group: Methotrexate group with pioglitazone, test dose of MTX is given in the amount of 15 mg by injection. 1 week later, CBC, liver enzymes and kidney function will be checked. If the tests are normal, the dose of 15 mg weekly systemically along with oral pioglitazone 15 mg daily is started for the patient.The minimum duration of treatment and follow-up is 6 months, and follow-up is done in months 0, 2, 4, and 6. Intervention 2: Control group: Methotrexate group, the test dose of MTX is given in the amount of 15 mg by injection. 1 week later, CBC, liver enzymes and kidney function will be checked. If the tests are normal, a weekly dose of 15 mg is started for the patient. The minimum duration of treatment and follow-up is 6 months, and follow-up is done in months 0, 2, 4, and 6. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is A decision will be made after the project is finished.